| We have made arrangements with Kings College, London to conduct Phase II trials at the institution on an opioid antagonist-based nasal spray treatment for Bulimia Nervosa. We aim to commence these trials early next year.
Bulimia Nervosa is a condition affecting approximately 5 million people in the US today, with only about 50% of these patients finding successful treatment options. We are applying the same science we are using to develop a treatment for Binge Eating Disorder to develop a solution for Bulimia Nervosa.
In partnering with Kings College, with its internationally recognized eating disorder unit, we believe that we have considerably strengthened our already distinguished research and development team. Professor Janet Treasure, head of the Eating Disorders Unit at the South London and Maudsley NHS Trust and author of several well-regarded books on eating disorders, and Professor Ulrike Schmidt, a consultant psychiatrist for the Eating Disorders Service and a fellow of the Academy for Eating Disorders, will be tremendous guides for these Phase II trials. |
